144 related articles for article (PubMed ID: 26454138)
1. Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Miller DA; Keen JM; Brough C; Ellenberger DJ; Cisneros M; Williams RO; McGinity JW
J Pharm Pharmacol; 2016 May; 68(5):678-91. PubMed ID: 26454138
[TBL] [Abstract][Full Text] [Related]
2. Solid self-microemulsifying drug delivery system of ritonavir.
Deshmukh A; Kulkarni S
Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
[TBL] [Abstract][Full Text] [Related]
3. Triple Strategies to Improve Oral Bioavailability by Fabricating Coamorphous Forms of Ursolic Acid with Piperine: Enhancing Water-Solubility, Permeability, and Inhibiting Cytochrome P450 Isozymes.
Yu D; Kan Z; Shan F; Zang J; Zhou J
Mol Pharm; 2020 Dec; 17(12):4443-4462. PubMed ID: 32926628
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions.
Dhore PW; Dave VS; Saoji SD; Bobde YS; Mack C; Raut NA
Pharm Dev Technol; 2017 Feb; 22(1):90-102. PubMed ID: 27291246
[TBL] [Abstract][Full Text] [Related]
5. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin.
Dengale SJ; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Biopharm; 2015 Jan; 89():329-38. PubMed ID: 25542681
[TBL] [Abstract][Full Text] [Related]
6. Development and optimisation of 3-Acetyl-11-keto-β-boswellic acid loaded poly-lactic-co-glycolic acid-nanoparticles with enhanced oral bioavailability and in-vivo anti-inflammatory activity in rats.
Bairwa K; Jachak SM
J Pharm Pharmacol; 2015 Sep; 67(9):1188-97. PubMed ID: 25851251
[TBL] [Abstract][Full Text] [Related]
7. Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet.
Ellenberger DJ; Miller DA; Kucera SU; Williams RO
AAPS PharmSciTech; 2018 Jul; 19(5):1985-1997. PubMed ID: 29869311
[TBL] [Abstract][Full Text] [Related]
8. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
[TBL] [Abstract][Full Text] [Related]
9. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
10. Enhanced oral bioavailability of paclitaxel by solid dispersion granulation.
Shanmugam S; Im HT; Sohn YT; Kim YI; Park JH; Park ES; Woo JS
Drug Dev Ind Pharm; 2015; 41(11):1864-76. PubMed ID: 25775012
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of ritonavir formulations and correlation to in vivo performance in dogs.
Xu H; Krakow S; Shi Y; Rosenberg J; Gao P
Eur J Pharm Sci; 2018 Mar; 115():286-295. PubMed ID: 29355594
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.
Law D; Schmitt EA; Marsh KC; Everitt EA; Wang W; Fort JJ; Krill SL; Qiu Y
J Pharm Sci; 2004 Mar; 93(3):563-70. PubMed ID: 14762895
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasticizers on manufacturing ritonavir/copovidone solid dispersions via hot-melt extrusion: Preformulation, physicochemical characterization, and pharmacokinetics in rats.
Zhao Y; Xie X; Zhao Y; Gao Y; Cai C; Zhang Q; Ding Z; Fan Z; Zhang H; Liu M; Han J
Eur J Pharm Sci; 2019 Jan; 127():60-70. PubMed ID: 30343153
[TBL] [Abstract][Full Text] [Related]
14. Biopharmaceutic
Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
[TBL] [Abstract][Full Text] [Related]
15. Formulation of Nanospanlastics as a Promising Approach for Improving the Topical Delivery of a Natural Leukotriene Inhibitor (3-Acetyl-11-Keto-β-Boswellic Acid): Statistical Optimization, in vitro Characterization, and ex vivo Permeation Study.
Badria F; Mazyed E
Drug Des Devel Ther; 2020; 14():3697-3721. PubMed ID: 32982176
[TBL] [Abstract][Full Text] [Related]
16. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
17. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
Yu H; Janssen JM; Sawicki E; van Hasselt JGC; de Weger VA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR
J Clin Pharmacol; 2020 Mar; 60(3):340-350. PubMed ID: 31595980
[TBL] [Abstract][Full Text] [Related]
18. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.
Mukherjee D; Zha J; Menon RM; Shebley M
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):443-456. PubMed ID: 29427135
[TBL] [Abstract][Full Text] [Related]
19. Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules, improving stability, palatability, and bioavailability.
Guo S; Pham K; Li D; Penzak SR; Dong X
Int J Nanomedicine; 2016; 11():1451-60. PubMed ID: 27103803
[TBL] [Abstract][Full Text] [Related]
20. Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.
Ravi PR; Vats R; Thakur R; Srivani S; Aditya N
Phytother Res; 2012 Oct; 26(10):1490-5. PubMed ID: 22308076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
